This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GEHC Stock Declines Despite the Unveiling of CareIntellect Application
by Zacks Equity Research
GE Healthcare announces CareIntellect for Oncology to provide multi-modal patient data from disparate systems into a single view using generative AI.
iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT
by Zacks Equity Research
IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
by Zacks Equity Research
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.77% and 3.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval
by Zacks Equity Research
BSX receives FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, enhancing cardiac mapping and ablation workflows for AF treatment.
Myriad Genetics Shares Fall Despite Partnership With jscreen
by Zacks Equity Research
MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.
Aurora Cannabis Stock Rises Following Medical Cannabis Oil Launch
by Zacks Equity Research
ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care.
Paragon 28's Shares Rise After Launch of Phantom Fibula Nail System
by Zacks Equity Research
FNA unveils Phantom Fibula Nail System, a less invasive, next-gen solution for ankle fractures, offering enhanced precision, stability and better patient outcomes.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
by Zacks Equity Research
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
by Zacks Equity Research
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GE HealthCare's Shares Rise After the Launch of Versana Premier
by Zacks Equity Research
GEHC launches Versana Premier, an AI-powered ultrasound system with advanced features designed for efficient, high-quality diagnostics across multiple specialties.
Quest Diagnostics (DGX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
by Zacks Equity Research
PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amwell Shares Rise After Expansion of Portfolio With Hello Heart
by Zacks Equity Research
AMWL adds Hello Heart to its clinical programs, offering heart health solutions to members with high blood pressure or cholesterol via its Converge platform.
DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?
by Zacks Equity Research
DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
by Zacks Equity Research
DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.
Here's Why You Should Add DaVita Stock to Your Portfolio Now
by Zacks Equity Research
DVA's strength in its kidney care business raises optimism about the stock.
Labcorp Stock Gains From Biopharma Business Amid FX Woe
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.
Here's Why You Should Add Masimo Stock to Your Portfolio Now
by Zacks Equity Research
MASI's R&D activities raise optimism about the stock.